Myocardial Glucose Metabolism Is Increased in Newly Diagnosed Lung Adenocarcinoma

Cardiology ◽  
2021 ◽  
pp. 1-9
Author(s):  
Jiaoyan Wu ◽  
Li Wang ◽  
Yuetao Wang ◽  
Min-Fu Yang
Keyword(s):  
Bone Marrow ◽  
Glucose Metabolism ◽  
Lung Adenocarcinoma ◽  
Fdg Pet ◽  
Arterial Wall ◽  
Left Ventricular ◽  
Newly Diagnosed ◽  
Myocardial Glucose Metabolism ◽  
Pet Ct ◽  
Fdg Pet Ct

<b><i>Background:</i></b> Cardiac metabolism alterations may be involved in abnormalities of cancer patients’ cardiovascular system. This study aimed to explore whether left ventricular myocardial glucose metabolism is altered and its related factors in newly diagnosed patients with lung adenocarcinoma (LAD) who underwent fluorine-18 fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT). <b><i>Methods:</i></b> From our <sup>18</sup>F-FDG PET/CT imaging database, 171 patients with newly diagnosed LAD and 43 nononcologic subjects with matched age and sex were retrospectively analyzed. The included patients underwent conventional <sup>18</sup>F-FDG PET/CT imaging with a &#x3e;12-h fasting before <sup>18</sup>F-FDG administration. The standardized uptake values (SUVs) of the left ventricular (LV) myocardium, arterial wall, epicardial adipose tissue (EAT), spleen, and bone marrow were separately measured. Laboratory parameters and echocardiographic results were collected as well. LAD patients were divided into 2 groups based on the 95th percentile of LV maximal SUV (SUV<sub>max</sub>) obtained from the 43 nononcologic subjects. Univariate analysis and multiple logistic regression analysis were used to identify significant factors. <b><i>Results:</i></b> Higher LV SUV<sub>max</sub> was found (3.8 [2.4, 7.7] vs. 3.0 [2.0, 5.4], <i>p</i> = 0.052) in LAD than that in nononcologic patients, whereas no significant differences of <sup>18</sup>F-FDG uptake were found in the arterial wall, EAT, spleen, or bone marrow between LAD patients and controls. The maximum diameter (<i>D</i><sub>max</sub>) of the LAD lesion, SUV<sub>max</sub> of spleen, and SUV<sub>max</sub> of EAT were related to LV SUV<sub>max</sub> in LAD. <b><i>Conclusions:</i></b> Myocardial glucose metabolism is increased in patients with newly diagnosed LAD. <i>D</i><sub>max</sub> of LAD lesion, spleen activity, and EAT activity contribute to the increased LV activity in LAD.

scholarly journals Enhanced glucose metabolism mediated by CD147 is associated with 18 F‐FDG PET/CT imaging in lung adenocarcinoma

2020 ◽  
Vol 11 (5) ◽  
pp. 1245-1257
Author(s):  
Yufan Zhang ◽  
Jianjing Liu ◽  
Yunchuan Sun ◽  
Xiaozhou Yu ◽  
Jian Wang ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Lung Adenocarcinoma ◽  
Fdg Pet ◽  
Ct Imaging ◽  
Pet Ct ◽  
Fdg Pet Ct

Role of FDG-PET/CT for Detection of Occult Bone Marrow Involvement in Patients from the Middle East and North Africa Region with Hodgkin Lymphoma

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5348-5348
Author(s):  
Moussab Damlaj ◽  
Giamal Edin Mohamed Gmati ◽  
Ghulam Syed ◽  
Mohsen Al Zahrani ◽  
Khadega Ahmed Abuelgasim ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Sensitivity And Specificity ◽  
Fdg Pet ◽  
Stage Iii ◽  
Newly Diagnosed ◽  
Mena Region ◽  
Bone Marrow Disease ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Initial Staging

Abstract Background: Routine bone marrow biopsy (BMB) for the initial staging of Hodgkin Lymphoma (HL) is not recommended in the era of FDG-PET/CT staging (J Clin Oncol. 2014;32(27):3059). However, patients from the Middle East and North Africa (MENA) region have epidemiologic and clinical features of lymphoma that are different from patients of other ethnicities (J Natl Compr Canc Net2010;8:S-29-S-35). Therefore, it is unknown whetherFDG-PET/CT can substitute for staging BMB in this population.At our center, we perform routine BMB for all newly diagnosed lymphoma cases. Aim: To investigate whether routine BMB is essential in detecting bone marrow disease where FDG-PET/CT is used in initial staging for HL in patients from the MENA region. Methods: Patients with HL at our institution between 2010 - 2015 were identified. Inclusion criteria included newly diagnosed patients who had BMB and FDG-PET/CT as part of initial staging. All baseline and laboratory features were retrospectively extracted. Pathology reports of bone marrow aspirate and trephine biopsies were reviewed by two independent Hematologists. All written FDG-PET/CT reports were retrieved and carefully reviewed and cases with positive skeletal uptake were re-interpreted by an experienced radiologist. Pattern of skeletal FDG-PET/CT uptake was determined and classified as unifocal or multifocal. Sensitivity and specificity was computed while defining bone marrow disease by positive BMB and / or focal skeletal uptake on FDG-PET/CT. Categorical and continuous variables were analyzed using Pearson's chi-squared and Student's t-test, respectively. Results: A. Baseline characteristics: A total of92 patients met the inclusion criteria and were considered for this analysis. All patients were from the MENA region and > 90% were from the Arabian peninsula. From this cohort, bone marrow disease was detected in 7 (7.6%) patients using BMB while 20 (21.7%) patients had unifocal or multifocal bone marrow uptake on FDG-PET/CT. An additional 21 patients (23%) had diffuse homogenous FDG uptake and was not considered to represent HL. The cohort was characterized by a male to female ratio of 1.4 and a median age at diagnosis of 27 years (6-83). About two thirds of the cases were classical HL of the nodular sclerosis subtype (Table 1). Almost 60% of cases were stage III - IV with corresponding median IPS of 2 (0-6). Incidence of bulky disease and B-symptoms among the entire cohort was 32% and 50%, respectively. B. Comparison of FDG-PET/CT and BMB No patient with involved BMB (iBMB) had early stage disease on FDG-PET/CT and BMB identified only one patient with positive BM involvement yet negative skeletal uptake on FED-PET/CT. Involvement by BMB upstaged 3 patients previously assessed by CT scan as having stage III, however, none of the patients were allocated to a different treatment plan based on the BMB result. On the other hand, FDG-PET/CT upstaged 24 patients (26%); 9 patients from stage III to IV and 14 patients from early to advanced stage resulting in change of therapeutic plan in the latter group. Focal skeletal FDG-PET/CT lesions identified positive marrow disease with a sensitivity and specificity of 95.2% and 70.4%, respectively. On the other hand, sensitivity and specificity of BMB was 35% and 100%, respectively (Table 2). Abnormal skeletal FDG uptake was seen in a total of 20 patients (21.7%); 11 (55%) had unifocal / bifocal while 9 (45%) had multifocal disease of the axial skeleton. Patients with iBMB compared to those with negative BMB but positive unifocal / multifocal skeletal FDG-PET/CT lesions were more likely to be male (p = 0.002), have B-symptoms (p = 0.028), extranodal disease (p = 0.017) and more likely to have multifocal uptake on FDG-PET/CT (0.017) (Table 3). Conclusion:To our knowledge, this is the first analysis to examine the role of FDG-PET/CT for detection of bone marrow involvement in HL in a patient cohort from the MENA region. We observed that FDG-PET/CT had a higher sensitivity and negative predictive value compared to BMB leading to a treatment change in a significant proportion of patients. This analysis highlightsthat FDG-PET/CT can substitute for BMB in routine staging for newly diagnosed patients with HL from the MENA region. Disclosures No relevant conflicts of interest to declare.

Suppression of myocardial glucose metabolism in FDG PET/CT: impact of dose variation in heparin bolus pre-administration

2020 ◽  
Vol 47 (11) ◽  
pp. 2698-2702 ◽  
Author(s):  
A. M. Scholtens ◽  
A. M. van den Berk ◽  
N. L. van der Sluis ◽  
J. P. Esser ◽  
G. K. Lammers ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Fdg Pet ◽  
Myocardial Glucose Metabolism ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Dose Variation

Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma

2016 ◽  
Vol 45 (4) ◽  
pp. 1082-1089 ◽  
Author(s):  
Domenico Albano ◽  
Caterina Patti ◽  
Roberto Lagalla ◽  
Massimo Midiri ◽  
Massimo Galia
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Biopsy ◽  
Fdg Pet ◽  
Bone Marrow Involvement ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Whole Body Mri ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Detection of bone marrow involvement with FDG PET/CT in patients with newly diagnosed lymphoma

2018 ◽  
Vol 53 (4) ◽  
pp. 281
Author(s):  
H. Tahsin Özpolat ◽  
Ebru Yilmaz ◽  
Hasan Sami Goksoy ◽  
Sahre Özpolat ◽  
Öner Dogan ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Fdg Pet ◽  
Bone Marrow Involvement ◽  
Newly Diagnosed ◽  
Pet Ct ◽  
Fdg Pet Ct

Role of FDG-PET/CT in Detecting Lymphomatous Bone Marrow Involvement in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 5204-5204
Author(s):  
Junshik Hong ◽  
Yukyung Lee ◽  
Seog Gyun Kim ◽  
Kyung Hoon Hwang ◽  
Soon Ho Park ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Fdg Pet ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Newly Diagnosed ◽  
Large B Cell Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Large B Cell

Abstract Abstract 5204 Backgrounds: As a bone marrow bopsy (BMB) is a painful and invasive procedure with a restrictive reliability as only a limited area of the bone marrow (BM) can be evaluated, role of FDG-PET/CT to demonstrate lymphomatous BM involvement as an alternative or at least a complementary to BMB is an area of interest. Several previous studies exist but most of them included heterogeneous types of lymphomas with various treatments. Patients and methods: To evaluate the role of FDG-PET/CT in detecting BM involvement, pre-treatment bilateral BMBs and FDG-PET/CT scans of 89 patients with diffuse large B-cell lymphoma (DLBCL) treated with standard immunochemotherapy, rituximab-CHOP were reviewed and analyzed. Uptake more than liver parenchyma intensity on FDG-PET/CT was interpreted as 'with a possibility' of involvement. The final interpretation on the possibility of BM involvement in each patient was reported after discussion among three nuclear medicine physicians and results of BMB were blinded at the time of FDG-PET/CT review. Fourteen patients (15.7%) had lymphomatous involvement based on BMB (BMB+) and 17 patients (19.1%) had the possibility of BM involvement on FDG-PET/CT (FDG-PET/CT+). Seventy-two patients (80.8%) had concordant results between BMB and FDG-PET/CT (7 patients were positive for both and 65 patients were negative for both), but 17 patients (19.2%) had a discordant interpretation (7 patients were BMB+ and FDG-PET/CT-, and 10 for BMB- and FDG-PET/CT+; table 1). Although BMB+ patients had an inferior 2-year EFS (37.0% vs. 79.8%, p < 0.001) and OS (36.3% vs. 81.0%, p < 0.001) compared to BMB- patients, no differences in EFS (62.6% vs. 72.7%, p = 0.185) and OS (59.4% vs. 78.0%, p = 0.146) were shown between FDG-PET/CT+ and FDG-PET/CT- patients. Six of 7 patients with BMB+ and FDG-PET/CT+ had a diffuse involvement on FDG-PET/CT whereas 9 of 10 patients with BMB- and FDG-PET/CT+ had a focal BM involvement on FDG-PET/CT (table 2). Six of 7 patients with diffuse involvement on FDG-PET/CT were BMB+ whereas only 1 of 10 patients with focal BM involvement on FDG-PET/CT were BMB+ (table 2). It is likely therefore that patients with diffuse BM involvement on FDG-PET/CT had higher probability for BMB+ and they might have poorer survival than those with focal BM involvement. Conclusion: The results suggest that FDG-PET/CT had a limited value to detect BM involvement in patients with DLBCL. It may not be justified to upgrade patient's Ann Arbor stage to IV according to focal hypermetabolic BM lesion on FDG-PET/CT. Until additional results on the role of FDG-PET/CT in detecting BM involvement available, FDG-PET/CT should be used as an adjuvant rather than an alternative in detecting BM involvement in patients with newly diagnosed DLBCL. Disclosures: No relevant conflicts of interest to declare.

scholarly journals 18F-FDG-PET/CT in Multiple Myeloma: High Intense PET Positive Lesions at Diagnosis Harbor Cytogenetic Adverse Subclones

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3260-3260
Author(s):  
Brian Østergaard ◽  
Anne L. Nielsen ◽  
Hanne E.H. Møller ◽  
Birgitte Preiss ◽  
Jon T. Asmussen ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Fdg Pet ◽  
Myeloma Cell ◽  
Newly Diagnosed ◽  
Focal Lesions ◽  
Bone Marrow Biopsies ◽  
Ct Guided ◽  
Fdg Uptake ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Aim:In multiple myeloma (MM), high intensity of FDG uptake in focal lesions measured as the standard uptake value (SUV) at diagnosis is associated to aggressive disease and reduced overall survival. However, the reason for high intensity FDG uptake in some focal lesions is unknown, but hypothetically such "hot" lesions could represent evolving myeloma sub-clones with particular characteristics, e.g. higher proliferative activity. We aimed to explore and characterize focal lesions with high FDG uptake and to compare the findings with random diagnostic bone marrow biopsies with lower FDG intensity or a biopsy from another lesion with lower FDG uptake. Thus, we have created a paired biopsy biobank that will be explored for molecular, biological, physiological and myeloma prognostic markers. Here we present our first data including results on morphology, immunohistochemistry, mutational, proliferative and cytogenetic status in the biopsies Material and methods: CT-guided biopsies from FDG-PET positive CT-visible focal lesions in sternum, sacrum, humerus, femoral, pubic and iliac bones were taken without complications depending on accessibility and safety in 14 newly diagnosed, untreated MM patients, 2 females and 12 males, aged 53-77 years. Patients that had received steroids or bisphosphonates were excluded. Bone marrow biopsies were taken as part of the normal diagnostic work-up, but included an extra biopsy and aspirate for research. FDG uptake in the regions of interest (ROI) at focal and random bone marrow biopsy was quantified by dedicated software (ROVER, ABX, Radeberg, Germany) to obtain the following variables: Lesion volumes, SUVmax, SUVpeak, cSUVmean (SUVmean corrected for partial volume effect). The paired biopsies were analyzed for: Myeloma plasma cells percentage (PC%), myeloma cell proliferation (Ki67 positive fraction of CD138 positive cells (Ki67/CD138%), myeloma cell MYC protein expression (MYC/CD138%), FISH aberrations in % of myeloma cells (del17p, del13q, del1p, amp1q, t(11;14), t(4;14), BRAF mutation and specific p16, p27, and p53 protein expressions by IHC in % of MM cells. Results: 13 patients were evaluable for analysis with paired datasets. One patient was excluded due to a normal bone marrow examination (multifocal myeloma). ROI SUVmax values ranged from 2.6 to 22.16 and differences in SUVmax between paired biopsies ranged from 0.4 to 17.1. First of all, we found myeloma malignancy in all PET-positive CT-guided biopsies. Comparing the findings in "hot" versus "random" biopsy groups we found significantly higher PC%s in the "hot" biopsy group (p=0.01) but this was not a consistent finding in all patients. PC proliferation rate (Ki67/CD138) was higher in some of the "hot" biopsies but this was neither a uniform observation. No difference in "primary event" chromosome 14q translocations was observed, whereas we identified subclones with typical cytogenetic secondary or late events in several "hot" biopsies that were not present in the random bone marrow biopsy: amp1q in 3 patients, del1p in 1 patient, del13q and del17p in 1 patient. MYC protein expression was higher in "hot" biopsies in 4 patients, and downregulation of p27 was evident in 2 patients. We found no unbalanced expression of p53 or p16, and in only one patient we identified a BRAF mutated subclone that was equally present in the "hot" and "random" biopsy (20% vs 30%). Few patients presented more adverse findings in the "hot" biopsies. Overall, MM adverse findings were present unbalancedly in 8 of 13 patients. Conclusion: We did not identify a mutual factor that explained the more intense FDG uptake in CT guided biopsies than in random bone marrow, e.g. a higher PC Ki67 expression. However, in 8 of 13 patients we identified 1 or more prognostic adverse, unbalanced findings in the PET positive focal lesions indicating presence of more aggressive subclones. These findings are concordant with the adverse prognostic importance of finding high-intense PET-positive focal lesions on FDG-PET/CT in newly diagnosed MM patients. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document